Original Article

Estimation of second line anti-tubercular drug susceptibility to Mycobacterium tuberculosis in clinical isolates

Abstract

Background and Objectives: Tuberculosis (TB) is an infectious disease that is among the most common in the world and is a leading cause of high mortality and morbidity. In India, there is very limited data on second line drug susceptibility testing. The aim of the study was to find out the prevalence of Multi Drug Resistant (MDR) isolates among Mycobacterium tuberculosis (MTB) complex strains and to assess the sensitivity pattern to four commonly used 2nd line anti-tubercular drugs irrespective of their MDR status.
Materials and Methods: A 61 culture-positive strains of the tuberculosis complex (smear positive or negative) in Mycobacterium Growth Indicator Tube (MGIT) and Lowenstein Jensen (LJ) from various clinical samples were included. We performed MGIT 1st and 2nd line susceptibility testing for tuberculosis.
Results: Among the 61 isolates, 12 (19.6%) were multi drug resistant. Capreomycin resistance was observed in 17 (27.8%) isolates, kanamycin resistance in 30 (49.1%), ofloxacin resistance in 5 (8.1%), and ethionamide resistance in 6 (9.8%) isolates. Resistance to kanamycin and ethionamide was more common among patients with multi drug resistant tuberculosis (MDR-TB) than among those with non-MDR-TB.
Conclusion: The MGIT system has surpassed solid culture and is an excellent method for performing culture and drug sensitivity testing for tuberculosis. However, its use remains limited by economic and logistical challenges. The high prevalence of aminoglycoside resistance suggests the need to preserve these drugs for treating patients with MDR-TB.

1. Zhao P, Fang F, Yu Q, Guo J, Zhang J-h, Qu J, et al. Evaluation of BACTEC MGIT 960 system for testing Susceptibility of Mycobacterium tuberculosis to First-Line drugs in China. PLoS One 2014; 9(9): e99659.
2. Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 2010; 14: 243-246.
3. Kuo CY, Wang WH, Huang CH, Chen YH, Lu PL. Resistance to first- and second-line antituberculosis drugs in southern Taiwan: Implications for empirical treatment. J Microbiol Immunol Infect 2018; 51: 88-93.
4. Viney K, Linh NN, Gegia M, Zignol M, Glaziou P, Ismail N, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respir J 2021; 57: 2100361.
5. Central TB Division. INDIA TB REPORT 2022 Coming Together to End TB Altogether. Central TB Division, Ministry of Health and Family Welfare. (2022).
6. Lawson L, Emenyonu N, Abdurrahman ST, Lawson JO, Uzoewulu GN, Sogaolu OM, et al. Comparison of Mycobacterium tuberculosis drug susceptibility using solid and liquid culture in Nigeria. BMC Res Notes 2013; 6: 215.
7. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31: 1209-1215.
8. Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2001; 39: 4440-4444.
9. Lohiya A, Suliankatchi Abdulkader R, Rath RS, Jacob O, Chinnakali P, Goel AD, et al. Prevalence and patterns of drug resistant pulmonary tuberculosis in India-A systematic review and meta-analysis. J Glob Antimicrob Resist 2020; 22: 308-316.
10. WHO (2021). Global tuberculosis report. World Health Organization, Geneva.
11. Mpagama SG, Houpt ER, Stroup S, Kumburu H, Gratz J, Kibiki GS, et al. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC Infect Dis 2013; 13: 432.
12. Chen Y, Yuan Z, Shen X, Wu J, Wu Z, Xu B. Resistance to Second-Line antituberculosis drugs and delay in drug susceptibility testing among multidrug-resistant tuberculosis patients in shanghai. Biomed Res Int 2016; 2016: 2628913.
13. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008; 12: 99-104.
14. Al-Soud WA, Jönsson LJ, Râdström P. Identification and characterization of immunoglobulin G in blood as a major inhibitor of diagnostic PCR. J Clin Microbiol 2000; 38: 345-350.
15. Bhardwaj A, Khan S, Kumar A, George L, Mehta A, Radhakrishnan K. Assessing the Utility of GeneXpert MTB/Rif Assay in a Tertiary Care Centre in Southern India with Established Microscopy and Liquid Culture Facilities. J Assoc Physicians India 2019; 67: 31-34.
16. Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Int J Infect Dis 2017; 56: 185-189.
Files
IssueVol 17 No 6 (2025) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v17i6.20361
Keywords
Mycobacterium tuberculosis Infections Antitubercular drugs Resistant
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Sudersanan H, Menon Ravikumar N, Mishra B. Estimation of second line anti-tubercular drug susceptibility to Mycobacterium tuberculosis in clinical isolates. Iran J Microbiol. 2025;17(6):936-941.